Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
This study aimed to evaluate the cost-utility of the addition of vericiguat for treating chronic heart failure (CHF) in China from the healthcare payer’s perspective.